Johnson & Johnson MedTech worldwide operational sales (change on a year)
MedTech worldwide operational sales (change on a year) at Johnson & Johnson came to 2.5% for the quarter to 27 Sep 2026, down 3.1 points from a year earlier.
As Johnson & Johnson reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 13 Oct 2026.
By quarter
| Period ending | MedTech worldwide operational sales (change on a year) | Change on a year | Filed |
|---|---|---|---|
| 27 Sep 2026 | 2.5% | down 3.1 points | 13 Oct 2026 |
| 28 Jun 2026 | 3.6% | down 2.5 points | 15 Jul 2026 |
| 29 Mar 2026 | 4.6% | up 0.5 points | 14 Apr 2026 |
| 28 Dec 2025 | 5.4% | down 0.8 points | 21 Jan 2026 |
| 28 Sep 2025 | 5.6% | down 0.8 points | 14 Oct 2025 |
| 29 Jun 2025 | 6.1% | up 1.7 points | 16 Jul 2025 |
| 30 Mar 2025 | 4.1% | down 2.2 points | 15 Apr 2025 |
| 29 Dec 2024 | 6.2% | down 6.2 points | 22 Jan 2025 |
| 29 Sep 2024 | 6.4% | down 4.0 points | 15 Oct 2024 |
| 30 Jun 2024 | 4.4% | down 10.3 points | 17 Jul 2024 |
| 31 Mar 2024 | 6.3% | down 4.7 points | 16 Apr 2024 |
| 31 Dec 2023 | 12.4% | — | 23 Jan 2024 |
| 1 Oct 2023 | 10.4% | — | 17 Oct 2023 |
| 2 Jul 2023 | 14.7% | — | 20 Jul 2023 |
| 2 Apr 2023 | 11.0% | — | 18 Apr 2023 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Shown as the change on the same period a year earlier, as the company prints it. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Johnson & Johnson: Oncology revenue · Immunology revenue · Neuroscience revenue · Cardiovascular revenue · Pulmonary Hypertension revenue · Cardiovascular/Metabolism/Other revenue · Infectious Diseases revenue · Shockwave revenue · Innovative Medicine revenue · MEDTECH revenue · United States revenue · Non-US revenue · Europe revenue · Asia-Pacific, Africa revenue · Western Hemisphere, excluding U.S. revenue · financial statements
Every KPI and segment of JNJ, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
